SBWire

The Obstetrics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the obstetrics partnering deals and agreements entered into by the worlds leading healthcare companies.

Endometriosis - Pipeline Review, H1 2014

Xerosis (Dry Skin) - Pipeline Review, H1 2014

GlobalData's clinical trial report, "Diabetic Retinopathy Global Clinical Trials Review, H1, 2014" provides data on the Diabetic Retinopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Retinopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Retinopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData's clinical trial report, "Glucose Intolerance Global Clinical Trials Review, H1, 2014" provides data on the Glucose Intolerance clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Glucose Intolerance. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Glucose Intolerance. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Cognitive Impairment - Pipeline Review, H1 2014

Acute Coronary Syndrome - Pipeline Review, H1 2014

Mild Cognitive Impairment - Pipeline Review, H1 2014

Dignity Sciences Ltd. - Product Pipeline Review - 2014

Constipation - Pipeline Review, H1 2014

Human Papillomavirus Infections - Pipeline Review, H1 2014

Abiogen Pharma S.p.A. - Product Pipeline Review - 2014

Relapsed Multiple Myeloma - Pipeline Review, H1 2014

Acne Vulgaris - Pipeline Review, H1 2014

The RSV Partnering 2009-2014 provides understanding and access to the RSV partnering deals and agreements entered into by the worlds leading healthcare companies.

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2014

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection.

Metastatic Ovarian Cancer - Pipeline Review, H1 2014

Premature Ejaculation - Pipeline Review, H1 2014

The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.

Onychomycosis (Tinea Unguium) - Pipeline Review, H1 2014

BioDelivery Sciences International, Inc. - Product Pipeline Review - 2014

Fatty Liver Disease - Pipeline Review, H1 2014

Glioblastoma Multiforme (GBM) - Pipeline Review, H1 2014

Neuropathic pain (NP) is defined as a disorder of the sensorimotor system and is distinctly different from nociceptive pain, which is a consequence of trauma, injury, or inflammation. The main difference between neuropathic and nociceptive pain is the absence of a continuous nociceptive input in neuropathic pain. Although the term neuropathic pain is used to describe a wide range of pain syndromes with varying etiologies, this report focuses on 3 distinct forms of NP: Painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia. The main classes of drugs used to treat these three neuropathic pain indications include anticonvulsants, antidepressants, opioids and topical treatments. However, despite the availability of multiple pain medications only 50% of patients respond to any given drug and there are numerous the side effects associated particularly with systemically administered drugs, that reduce their tolerability.